Divyesh Sharma is a Senior Healthcare Writer at Ailoitte & writes about medical software regulatory pathways and the influence on engineering.

Hyperfine's Q3 revenue topped cash burn for the first time, marking a major step toward capital efficiency and profitability.

AAHKS warns Medicare's 2027 cuts to hip and knee replacement payments threaten procedure volumes, tech adoption, and medtech ...

Senseonics' Q3 2026 revenue grew 140% YoY, driving raised full-year guidance and a 30%+ stock surge to a 52-week high.

Forget Congress — the real medtech question for 2027 is whether hospital customers can still afford capital equipment ...

FDA denied Novocure's PMA for Optune Mya, citing a lack of clinical benefit evidence, though no safety concerns were raised.

Simtra's Mike Schaefer on how the GLP-1 boom is reshaping CDMO strategy, from regional manufacturing to cold-chain capacity.

Check out these 10 editorial nominees for the 2026 Medtech Company of the Year, then vote for your choice at the end of the list.

The softer sales, along with reimbursement pressure in wound care, caused the London-based company to miss Wall Street ...

Edwards Lifesciences raised its 2026 guidance for the third time this year, citing strong TAVR growth, new clinical data, and ...

Understanding the realities patients face when using devices outside the hospital requires, well, getting out of the hospital ...

Boston Scientific cuts Q4 guidance as cyberattack fallout and EP and Watchman market pressures weigh on growth heading into ...